Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Trial Profile

Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Momelotinib (Primary)
  • Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 29 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
    • 27 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top